6V0R image
Deposition Date 2019-11-19
Release Date 2020-04-01
Last Version Date 2024-11-20
Entry Detail
PDB ID:
6V0R
Keywords:
Title:
BG505 SOSIP.664 Trimer
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.87 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:BG505 SOSIPv5.2 gp120
Gene (Uniprot):env
Chain IDs:A, C, E (auth: D)
Chain Length:475
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Polymer Type:polypeptide(L)
Molecule:BG505 SOSIPv5.2 gp41
Gene (Uniprot):env
Chain IDs:B, D (auth: E), F
Chain Length:153
Number of Molecules:3
Biological Source:Human immunodeficiency virus 1
Ligand Molecules
Primary Citation
Mapping Polyclonal Antibody Responses in Non-human Primates Vaccinated with HIV Env Trimer Subunit Vaccines.
Cell Rep 30 3755 3765.e7 (2020)
PMID: 32187547 DOI: 10.1016/j.celrep.2020.02.061

Abstact

Rational immunogen design aims to focus antibody responses to vulnerable sites on primary antigens. Given the size of these antigens, there is, however, potential for eliciting unwanted, off-target responses. Here, we use our electron microscopy polyclonal epitope mapping approach to describe the antibody specificities elicited by immunization of non-human primates with soluble HIV envelope trimers and subsequent repeated viral challenge. An increased diversity of epitopes recognized and the approach angle by which these antibodies bind constitute a hallmark of the humoral response in most protected animals. We also show that fusion peptide-specific antibodies are likely responsible for some neutralization breadth. Moreover, cryoelectron microscopy (cryo-EM) analysis of a fully protected animal reveals a high degree of clonality within a subset of putatively neutralizing antibodies, enabling a detailed molecular description of the antibody paratope. Our results provide important insights into the immune response against a vaccine candidate that entered into clinical trials in 2019.

Legend

Protein

Chemical

Disease

Primary Citation of related structures